Critical Review: Daré Bioscience (NASDAQ:DARE) versus Pasithea Therapeutics (NASDAQ:KTTA)

Pasithea Therapeutics (NASDAQ:KTTA) and Daré Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Volatility & Risk

Pasithea Therapeutics has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.

Profitability

This table compares Pasithea Therapeutics and Daré Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-81.57%	-74.31%
Daré Bioscience	-191.65%	N/A	-18.98%

Institutional and Insider Ownership

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Daré Bioscience shares are held by institutional investors. 16.3% of Pasithea Therapeutics shares are held by insiders. Comparatively, 4.0% of Daré Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Pasithea Therapeutics and Daré Bioscience, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	0	0	0	0	0.00
Daré Bioscience	0	2	2	0	2.50

Daré Bioscience has a consensus price target of $24.00, indicating a potential upside of 618.56%. Given Daré Bioscience’s stronger consensus rating and higher possible upside, analysts clearly believe Daré Bioscience is more favorable than Pasithea Therapeutics.

Earnings & Valuation

This table compares Pasithea Therapeutics and Daré Bioscience”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	$20,000.00	196.85	-$15.96 million	N/A	N/A
Daré Bioscience	$1.88 million	15.45	-$30.16 million	($0.59)	-5.66

Pasithea Therapeutics has higher earnings, but lower revenue than Daré Bioscience.

Summary

Daré Bioscience beats Pasithea Therapeutics on 7 of the 12 factors compared between the two stocks.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

About Daré Bioscience

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.